RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerCristina Cruz, Violeta Serra, Marta Castroviejo‐Bermejo et al.|Annals of Oncology|2018Cited by 424
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Mandy Ducy et al.|EMBO Molecular Medicine|2018Cited by 271
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug EvaluationQueralt Serra-Camprubí, Tian V. Tian, Helena Verdaguer et al.|Clinical Cancer Research|2022Cited by 22
Supplementary Table S5 from Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug EvaluationQueralt Serra-Camprubí, Tian V. Tian, Helena Verdaguer et al.|Unknown|2023Cited by 0